US Stock MarketDetailed Quotes
GLTO Galecto
- 5.510
- -0.040-0.72%
Close Nov 27 16:00 ET
7.26MMarket Cap-288P/E (TTM)
5.980High5.510Low12.07KVolume5.650Open5.550Pre Close68.18KTurnover1.00%Turnover RatioLossP/E (Static)1.32MShares23.50052wk High0.35P/B6.68MFloat Cap5.51052wk Low--Dividend TTM1.21MShs Float449.750Historical High--Div YieldTTM8.46%Amplitude5.510Historical Low5.650Avg Price1Lot Size
About Galecto Company
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3, lysyl oxidase-like 2, and LOXL2. The company was founded by Ulf J?rgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsg?rd Schambye in 2011 and is headquartered in Boston, MA.
Company Profile
SymbolGLTO
Company NameGalecto
Listing DateOct 29, 2020
Issue Price15.00
Founded2011
CEODr. Hans T. Schambye, M.D.,PhD
MarketNASDAQ
Employees13
Fiscal Year Ends12-31
Address75 State Street,Suite 100
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02109
Phone1-45-070-5210
Websitehttp://www.galecto.com
Company Executives
- Name
- Position
- Salary
- Dr. Hans T. Schambye, M.D.,PhD
- Director, President and Chief Executive Officer
- 965.12K
- Jonathan Freve
- Chief Financial Officer and Principal Accounting Officer
- 701.33K
- Dr. Carl S. Goldfischer,M.D.
- Chairman of the Board
- 155.19K
- Amit D. Munshi
- Independent Director
- 78.85K
- Dr. David Shapiro, M.D.
- Independent Director
- 148.84K
- Dr. Soren Moller, PhD
- Independent Director
- --
- Dr. Anne Prener, M.D.,PhD
- Independent Director
- 83.85K
- Dr. Amy B. Wechsler, M.D.
- Independent Director
- --
- Dr. Jayson Dallas, M.D.
- Independent Director
- 86.35K
- Garrett Winslow
- General Counsel and Corporate Secretary
- 554.39K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data